行情

ATNM

ATNM

Actinium Pharmac
AMEX

实时行情|Nasdaq Last Sale

5.63
+0.13
+2.36%
盘后: 5.63 0 0.00% 19:13 05/27 EDT
开盘
5.50
昨收
5.50
最高
5.63
最低
5.32
成交量
21.99万
成交额
0
52周最高
10.30
52周最低
4.410
市值
1.34亿
市盈率(TTM)
-4.9360
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解ATNM最新的财务预测,通过ATNM每股收益,每股净资产,每股现金流等数据分析Actinium Pharmac近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

20.00%强力推荐
80.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ATNM价格均价为29.25,最高价位45.00,最低价为22.00。
最高45.00
均价29.25
最低22.00
现价5.63
EPS
实际EPS
预期EPS
-0.080.210.490.78
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 42
机构持股: 2,339.65万
持股比例: 98.37%
总股本: 2,378.45万
类型机构数股数
增持
10
554.20万
建仓
5
1,091.19万
减持
6
158.86万
平仓
5
30.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+3.72%
制药与医学研究
+1.28%
高管信息
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Secretary
Steve O'Loughlin
Other
Avinash Desai
Other
Arun Swaminathan
Lead Director/Independent Director
C. David Nicholson
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Independent Director
Richard Steinhart
暂无数据
暂无数据
ATNM 简况
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATNM股票基本功能。